Machine Learning-Assisted Multimodal Early Screening of Lung Cancer Based on a Multiplexed Laser-Induced Graphene Immunosensor.

Authors

Cai Y,Ke L,Du A,Dong J,Gai Z,Gao L,Yang X,Han H,Du M,Qiang G,Wang L,Wei B,Fan Y,Wang Y

Affiliations (8)

  • Key Laboratory of Biomechanics and Mechanobiology, Ministry of Education, Beijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, Beihang University, Beijing 100191, China.
  • Department of Thoracic Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
  • School of Mechanical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250353, China.
  • School of Pharmacy, Liaocheng Vocational and Technical College, Liaocheng 252000, China.
  • School of Management, Wuhan University of Technology, Wuhan, Hubei 430070, China.
  • People's Hospital of Rizhao, Rizhao, Shandong 276825, China.
  • Department of Emergency, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
  • Department of Thoracic Surgery, Peking University Third Hospital, Beijing 100191, China.

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide, largely due to late-stage diagnosis. Early detection is critical for improving patient outcomes, yet current screening methods, such as low-dose computed tomography (CT), often lack the sensitivity and specificity required for early-stage detection. Here, we present a multimodal early screening platform that integrates a multiplexed laser-induced graphene (LIG) immunosensor with machine learning to enhance the accuracy of lung cancer diagnosis. Our platform enables the rapid, cost-effective, and simultaneous detection of four tumor markers─neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), p53, and SOX2─with limits of detection (LOD) as low as 1.62 pg/mL. By combining proteomic data from the immunosensor with deep learning-based CT imaging features and clinical data, we developed a multimodal predictive model that achieves an area under the curve (AUC) of 0.936, significantly outperforming single-modality approaches. This platform offers a transformative solution for early lung cancer screening, particularly in resource-limited settings, and provides potential technical support for precision medicine in oncology.

Topics

Journal Article

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.